Fovea Jewelry Holdings Ltd
Change company Symbol lookup
Select an option...
FJHL Fovea Jewelry Holdings Ltd
BML-J Bank of America Corp
PEP PepsiCo Inc
AGNC Agnc Investment Corp
ACM AECOM
CLSN Celsion Corp
BAC Bank of America Corp
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
Go

Company profile

Fovea Jewelry Holdings Ltd, formerly Wincash Resources, Inc., is a holding company engaged in the retail jewelry business. The Company intends to open free-standing retail stores under the brand name Fovea. It will market the Fovea brand of jewelry in key cities in Asia.

Closing Price
$0.1815
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.1815
Day's Low
0.1815
Volume
(Heavy Day)
Volume:
520

10-day average volume:
580
520

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

9:45 pm ET November 11, 2020 (PR Newswire) Print

Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Supernus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On November 9, 2020, post-market, Supernus disclosed receipt of a complete response letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding its new drug application ("NDA") for SPN-812 for the treatment of ADHD in pediatric patients aged 6-17 years old. Specifically, the FDA's CRL "indicate[d] that the review cycle for the application is complete and that the application is not ready for approval in its present form," and that "[t]he primary issue cited in the SPN-812 CRL relates to the Company's in-house laboratory that conducts analytical testing, which recently moved to a new location."

On this news, Supernus's stock price fell $3.88 per share, or 15.53%, to close at $21.08 per share on November 10, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com 888-476-6529 ext. 7980

https://c212.net/c/img/favicon.png?sn=DC89368&sd=2020-11-11

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-supernus-pharmaceuticals-inc---supn-301171454.html

SOURCE Pomerantz LLP

https://rt.prnewswire.com/rt.gif?NewsItemId=DC89368&Transmission_Id=202011112145PR_NEWS_USPR_____DC89368&DateId=20201111

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.